Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization

Recruiting now

Conditions studied: Kidney Transplant

In brief

In transplantation, B lymphocytes are major cellular players in the alloreactive humoral response through the production of antibodies targeting allogeneic HLA molecules expressed by the transplant. In subjects sensitized to HLA antigens, the contribution of pre-existing alloreactive memory B lymphocytes (Bmem) to allograft rejection phenomena after transplantation is now recognized. It has been proposed that the identification of these Bmem during the pre-transplant period could contribute to a better assessment of post-transplant immunological risk, allowing optimization of strategies to prevent humoral rejection. However, knowledge regarding the phenotypic and functional heterogeneity of Bmem as well as their clonal diversity is still extremely limited, not allowing discrimination between pathogenic and non-pathogenic alloreactive humoral responses. Such discrimination requires a better understanding of the modalities of differentiation of alloreactive B lymphocyte responses. To this end, this study aims to characterize the clonal, phenotypic and functional properties of alloreactive Bmem in subjects awaiting renal transplantation and sensitized to HLA antigens.

Key facts

Study ID

NCT07011238

Run by

University Hospital, Rouen

People needed

51

Starts

2023-04-17

Expected to finish

2028-06-17

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Rouen University Hospital patient monitored in the Nephrology and Kidney Transplantation Department, registered on the national kidney transplant waiting list
• Carrier of HLA antibodies, including at least anti-HLA2, identified during the last screening
• Notion of classic immune-promoting events including at least one previous transplant or pregnancy, or absence of a known immune-promoting event (naïve patient group)
• Incompatible graft rate (IGR)
• IGR ≥ 85% (hyperimmunized patient group with anti-HLA polyreactivity) or
• IGR between 50% and 85% (immunized patient group with a more restricted repertoire of HLA reactivities) or
• IGR < 50% (naïve patient group with no known history of immune-promoting events)
• Person who has read and understood the information letter and does not object Not participating in the study
• Affiliation to a social security scheme

You may not qualify if…

• Patients who have received rituximab in the previous year (B-cell depleting therapy)
• Patients undergoing an HLA desensitization protocol using plasmapheresis and/or rituximab
• Patients with an active infection
• Persons deprived of their liberty by an administrative or judicial decision or persons placed under judicial protection/guardianship or curatorship

Where it is running

• University Hopsital of Rouen — Rouen, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.